Systolic dysfunction has an important effect on cardiovascular outcomes and is associated with cognitive decline [2]. The relationship between diastolic dysfunction and cognition is undefined, however. To this end, Parker et al. analysed echocardiographic, MRI, and neuropsychological data, collected  between 2005-2008 in 1,438 participants >55 years in the Framingham Heart Study Offspring Cohort.
The outcomes demonstrated that an increasing E/Eâ ratio (early mitral filling/diastolic mitral annular velocity) was associated with increased incident mild cognitive impairment (HR 1.29; 95% CI 1.01-1.66; P<0.043) and an increase in executive function impairment in the Similarities (P<0.002) and Phonemic Fluency (P<0.001) tasks. Participants with moderate-to-severe diastolic dysfunction were more impaired on both tasks (P<0.046 and P<0.023, respectively). In 1,217 participants, those with mild diastolic dysfunction showed a trend towards increased white matter hyperintensities (portion of total cranial volume=0.11±0.07, P<0.105); those with moderate-to-severe diastolic dysfunction had increased white matter hyperintensities (0.30±0.09, P<0.001). The authors noted that these results align well with clinical findings in cerebral small vessel disease, as this usually presents with executive dysfunction.
- Parker A, et al. Abstract S15.005, AAN 2020.
- ZuccalĂ , et al. Am J Med. 2005;118(5):496-502.
Posted on
Previous Article
« Advanced breast cancer: locoregional therapy does not improve OS Next Article
News on AD biomarkers »
« Advanced breast cancer: locoregional therapy does not improve OS Next Article
News on AD biomarkers »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimerâs disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinsonâs disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles
September 9, 2020
Sleep disorders mark PD progression
September 10, 2020
Fampridine treatment results in routine clinical practice
September 10, 2020
Reassuring real-world safety profile of 3 CGRP inhibitors
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com